

Chlorambucil versus chlorambucil plus rituximab versus rituximab alone in malt lymphoma

Submission date 18/06/2010	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 18/06/2010	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 19/10/2018	Condition category Cancer	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

<http://cancerhelp.cancerresearchuk.org/trials/a-trial-looking-at-chlorambucil-alone-rituximab-alone-or-chlorambucil-and-rituximab-together-for-malt-lymphoma>

Contact information

Type(s)

Scientific

Contact name

Mrs Louisa Little

Contact details

MP131, University of Southampton Clinical Trials Unit
Tremona Road
Southampton
United Kingdom
SO16 6YD
+44 23 8120 5331
lal@soton.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

Study information

Scientific Title

Multi-centre randomised trial of chlorambucil versus chlorambucil plus rituximab versus rituximab alone in extranodal marginal zone b-cell lymphoma of mucosa associated lymphoid tissue (malt lymphoma)

Acronym

IELSG19/MALT Trial

Study objectives

The aim of the study is to assess the therapeutic activity and the safety of the combination of chlorambucil and rituximab in mucosa associated lymphoid tissue (MALT) lymphomas and to determine whether the addition of rituximab to chlorambucil will improve the outcome of MALT lymphoma in comparison to treatment with chlorambucil alone. Also to compare the anti-tumor activity and safety of rituximab alone versus chlorambucil alone.

Ethics approval required

Old ethics approval format

Ethics approval(s)

South East Multi-Centre Research Ethics Committee, 30/04/2003 (ref: 03/1/031). Amendment approved on the 30/10/2006.

Study design

Multicentre randomised interventional treatment trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Topic: National Cancer Research Network; Subtopic: Lymphoma; Disease: Lymphoma (non-Hodgkin's)

Interventions

ARM A: Chlorambucil 6 mg/m² daily orally (p.o.) for 42 consecutive days (weeks 1 - 6)
ARM B: Chlorambucil 6 mg/m² daily p.o. for 42 consecutive days (weeks 1 - 6) and rituximab 375 mg/m² intravenous (iv) on days 1, 8, 15, 22 during the first month (4 weekly doses)
ARM C: Rituximab 375 mg/m² iv on days 1, 8, 15, 22 during the first month (4 weekly doses)

Study entry: single randomisation only

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

Chlorambucil, rituximab

Primary outcome measure

Event-free-survival (EFS) (failure or death from any cause) for all patients

Secondary outcome measures

1. Complete and partial remission rates for all patients
2. Response duration (time to relapse or progression) for responder patients
3. Progression-free-survival (PFS) (disease progression or death from lymphoma: for all patients
4. Overall survival for all patients
5. Acute and long-term toxicity

Overall study start date

01/08/2003

Completion date

30/06/2010

Eligibility

Key inclusion criteria

To be eligible for inclusion in this trial, patients must fulfill all the following criteria:

1. Histologically proven diagnosis of CD20-positive marginal zone B-cell lymphoma of MALT type arisen at any extranodal site
2. Any stage (Ann Arbor I - IV)
3. Either de novo, or relapsed disease following local therapy (including surgery, radiotherapy and antibiotics for H. pylori-positive gastric lymphoma)
4. No evidence of histologic transformation to a high grade lymphoma
5. Measurable or evaluable disease
6. Aged greater than 18 years
7. Life expectancy of at least 1 year
8. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2
9. No prior diagnosis of neoplasm within 5 years, except cervical intraepithelial neoplasia type 1 (CIN1) or localised non-melanomatous skin cancer
10. No prior chemotherapy
11. No prior immunotherapy with any anti-CD20 monoclonal antibody

12. No prior radiotherapy in the last 6 weeks
13. No corticosteroids during the last 28 days, unless prednisone chronically administered at a dose less than 20 mg/day for indications other than lymphoma or lymphoma-related symptoms
14. No evidence of clinically significant cardiac disease, as defined by history of symptomatic ventricular arrhythmias, congestive heart failure or myocardial infarction within 12 months before study entry
15. No evidence of symptomatic central nervous system (CNS) disease
16. No impairment of bone marrow function (white blood cells [WBC] greater than $3.0 \times 10^9/L$, absolute neutrophil count [ANC] greater than $1.5 \times 10^9/L$, platelets [PLT] greater than $100 \times 10^9/L$), unless due to lymphoma involvement
17. No major impairment of renal function (serum creatinine less than 1.5 x upper normal) or liver function (aspartate aminotransferase [ASAT]/alanine aminotransferase [ALAT] less than 2.5 upper normal, total bilirubin less than 2.5 x upper normal), unless due to lymphoma involvement
18. No evidence of active opportunistic infections
19. No known human immunodeficiency virus (HIV) infection
20. No active hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection
21. No pregnant or lactating status
22. Appropriate contraceptive method in women of childbearing potential or men
23. Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
24. Informed consent must be given according to national/local regulations before randomisation

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

Planned sample size: 450

Key exclusion criteria

Does not meet inclusion criteria

Date of first enrolment

01/08/2003

Date of final enrolment

30/06/2010

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

MP131, University of Southampton Clinical Trials Unit

Southampton

United Kingdom

SO16 6YD

Sponsor information

Organisation

Southampton University Hospitals NHS Trust (UK)

Sponsor details

Tremona Road

Southampton

England

United Kingdom

SO16 6YD

Sponsor type

Hospital/treatment centre

Website

<http://www.soton.ac.uk/>

ROR

<https://ror.org/0485axj58>

Funder(s)

Funder type

Research organisation

Funder Name

International Extranodal Lymphoma Study Group (UK)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Plain English results				No	Yes